MedTrace Logo

A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes

NCT00838916 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 779

Last updated 2017-01-09

Study results available
· View outcomes & findings →

Summary

A study to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

BIOLOGICAL

albiglutide

albiglutide weekly injection

DRUG

insulin glargine

insulin glargine

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2012-01-31
Completion
2013-05-31

Countries

  • United States
  • Russia
  • South Africa
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00838916 on ClinicalTrials.gov